Atezolizumab

Generic Name
Atezolizumab
Brand Names
Tecentriq
Drug Type
Biotech
Chemical Formula
-
CAS Number
1380723-44-3
Unique Ingredient Identifier
52CMI0WC3Y
Background

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication

Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions
Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
Associated Therapies
-
Clinical Trials
Related News

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

First Posted Date
2017-07-28
Last Posted Date
2022-08-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1758
Registration Number
NCT03232593
Locations
🇰🇷

Dongnam Inst.of Radiological & Medical Sciences, Busan, Korea, Republic of

🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

🇰🇷

Inje university Haeundae Paik Hospital, Busan, Korea, Republic of

and more 52 locations

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

First Posted Date
2017-07-25
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT03228537
Locations
🇺🇸

Illinois CancerCare-Carthage, Carthage, Illinois, United States

🇺🇸

Centralia Oncology Clinic, Centralia, Illinois, United States

🇺🇸

Carle at The Riverfront, Danville, Illinois, United States

and more 176 locations

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Early Phase 1
Terminated
Conditions
Urothelial Carcinoma
Interventions
Drug: Atezolizumab
Drug: Radium-223
First Posted Date
2017-07-05
Last Posted Date
2018-10-24
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
1
Registration Number
NCT03208712
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2017-07-02
Last Posted Date
2024-10-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
75
Registration Number
NCT03206047
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 14 locations

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

First Posted Date
2017-07-02
Last Posted Date
2024-12-12
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
106
Registration Number
NCT03206203
Locations
🇺🇸

Indiana University Health Melvin Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

First Posted Date
2017-06-28
Last Posted Date
2024-04-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
86
Registration Number
NCT03201458
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 38 locations

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

First Posted Date
2017-06-28
Last Posted Date
2024-10-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT03202316
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

First Posted Date
2017-06-27
Last Posted Date
2024-08-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
190
Registration Number
NCT03199885
Locations
🇺🇸

Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States

and more 669 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

First Posted Date
2017-06-20
Last Posted Date
2024-11-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
340
Registration Number
NCT03193190
Locations
🇺🇸

Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 24 locations

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

First Posted Date
2017-06-08
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT03181100
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy